NASDAQ:HOTH - Hoth Therapeutics Stock Price, Forecast & News

Hoth Therapeutics trades on the NASDAQ under the ticker symbol "HOTH."

Hoth Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Hoth Therapeutics.

2 brokers have issued 12-month target prices for Hoth Therapeutics' stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Hoth Therapeutics' stock price to reach $10.00 in the next year. This suggests a possible upside of 121.2% from the stock's current price. View Analyst Price Targets for Hoth Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hoth Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hoth Therapeutics.

News stories about HOTH stock have been trending very positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Hoth Therapeutics earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Hoth Therapeutics.

Hoth Therapeutics saw a drop in short interest in January. As of January 31st, there was short interest totalling 19,300 shares, a drop of 49.6% from the January 15th total of 38,300 shares. Based on an average trading volume of 28,000 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.4% of the shares of the stock are short sold. View Hoth Therapeutics' Current Options Chain.

Some companies that are related to Hoth Therapeutics include Ovid Therapeutics (OVID), Neptune Wellness Solutions (NEPT), Tyme Technologies (TYME), Avenue Therapeutics (ATXI), Northwest Biotherapeutics (NWBO), ContraFect (CFRX), OASMIA PHARMACE/ADR (OASM), Marinus Pharmaceuticals (MRNS), Harrow Health (HROW), Selecta Biosciences (SELB), Aptinyx (APTX), vTv Therapeutics (VTVT), Adamas Pharmaceuticals (ADMS), Mustang Bio (MBIO) and Verastem (VSTM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include Verizon Communications (VZ), NovaBay Pharmaceuticals (NBY), Citius Pharmaceuticals (CTXR), Huntington Bancshares (HBAN), Inseego (INSG), People's United Financial (PBCT), Sesen Bio (SESN), Walgreens Boots Alliance (WBA), Energy Transfer LP Unit (ET) and General Motors (GM).

(HOTH) raised $8 million in an IPO on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

Shares of HOTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HOTH stock can currently be purchased for approximately $4.52.

Hoth Therapeutics has a market capitalization of $45.74 million. The company earns $-2,500,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Hoth Therapeutics employs 2 workers across the globe.View Additional Information About Hoth Therapeutics.

The official website for Hoth Therapeutics is http://www.hoththerapeutics.com/.

Hoth Therapeutics' mailing address is 1 Rockefeller Plaza Suite 1039, New York NY, 10020. The company can be reached via phone at 646-756-2997 or via email at [email protected]